Drugs / Tri Fluvac
Tri Fluvac
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02894840 Comparator | Nov 2015 → Jul 2016 | influenza | Mahidol University | Completed | No outcome recorded |
| Phase 2/3 | NCT03390166 Comparator | Jul 2017 → Mar 2018 | influenza | Mahidol University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tri Fluvac | “The study is aim to evaluate the safety and immunogenicity of one dose (15 μg HA per strain per dose) of the GPO seasonal trivalent inactivated split virion influenza vaccine...” NCT02894840 ↗ |
| Known as | GPO Tri Fluvac | “630 participants will be randomized to receive the GPO Tri Fluvac and 315 will receive an active comparator” NCT03390166 ↗ |
| Known as | GPO Tri Fluvac vaccine | “GPO Tri Fluvac vaccine” NCT03390166 ↗ |
| Modality | Vaccine | “seasonal trivalent split, inactivated influenza vaccine” NCT03390166 ↗ |
| Route | Intramuscular | “The vaccine will be administered via the intramuscular route” NCT03390166 ↗ |